Drug Type Bispecific antibody |
Synonyms ULBP2-BB4 |
Target |
Mechanism CD138 inhibitors(Syndecan-1 inhibitors), NKG2D agonists(NKG2-D type II integral membrane protein agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | DE | 01 Mar 2006 |